Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

AN OFF-THE-SHELF VACCINE FOR TRIPLE-NEGATIVE BREAST CANCER

Ziel

Recent studies have demonstrated that mRNA-based vaccines targeting neoantigens, in combination with immune checkpoint blockade, can elicit robust anti-tumour responses across multiple cancer types. These advances have propelled the cancer vaccine market towards a projected growth from $7 billion to $19 billion by 2033. Despite this promise, critical technological hurdles remain. Current antigen selection strategies rely heavily on computationally predicted neoantigens, yet the majority fail to elicit detectable immune responses. Paradoxically, clinical evidence confirms that increasing the number of immunogenic tumour antigens per vaccine correlates with improved patient benefit. This underscores the urgent need for antigen repertoires that extend beyond mutation-derived neoantigens. Moreover, because neoantigens are patient-specific, current vaccines must be personalized, introducing substantial manufacturing costs and logistical complexity. TWISTAR addresses these limitations by advancing a next-generation vaccination strategy that incorporates not only somatic mutations but also functionally validated, shared tumour antigens derived from the ‘dark’ genome, which represents a rich and largely untapped source of immunogenic targets. By analysing tumour biopsies from triple-negative breast cancer (TNBC) patients, we have identified 10 such ‘dark’ antigens. In a co-development partnership with myNEO Therapeutics, we will now evaluate the immunogenicity of these shared antigens and assess how many TNBC patients are capable of mounting a T-cell response against them. If successful, these validated dark antigens will translate into an off-the-shelf vaccine that complements immune checkpoint blockade and reduces the recurrence risk of triple-negative breast cancer.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

VIB VZW
Netto-EU-Beitrag
€ 150 000,00
Adresse
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgien
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)